Novo Nordisk stock soars after FDA approves first oral GLP-1 for weight loss

The FDA approval includes indications to reduce excess body weight, maintain weight reduction long-term, and reduce the risk of major adverse cardiovascular events. The pill’s safety and tolerability profile was consistent with previous semaglutide trials for weight management.

"The pill is here. With today’s approval of the Wegovy pill, patients will have a convenient, once-daily pill that can help them lose as much weight as the original Wegovy injection," said Mike Doustdar, president and CEO of Novo Nordisk.

Novo Nordisk plans to launch the Wegovy pill in the U.S. in early January 2026. 

Is it time to buy Novo again?